Jubilant Ingrevia Ltd. AI Stock Analysis
Want to see IN:JUBLINGREA full AI Analyst Report?
Jubilant Ingrevia Ltd. (JUBLINGREA) AI Stock Analysis
Jubilant Ingrevia Ltd.
(NSE:JUBLINGREA)
The score is held back primarily by weak cash-flow quality and volatility despite positive operating cash flow, alongside soft technical momentum (below key moving averages with negative MACD). A manageable balance sheet and modest revenue growth provide partial support, but a high P/E and low dividend yield further limit the score.
Jubilant Ingrevia Ltd. (JUBLINGREA) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 94.91B
- Dividend Yield
- 0.85%
- Average Volume (3M)
- 42.10K
- Price to Earnings (P/E)
- 26.5
- Beta (1Y)
- 1.02
- Revenue Growth
- 15.41%
- EPS Growth
- 21.76%
- Country
- India
- Employees
- 2,185
- Sector
- General
- Sector Strength
- 55
- Industry
- Chemicals - Specialty
Jubilant Ingrevia Ltd. Business Overview & Revenue Model
Company Description
Jubilant Ingrevia Limited, established in 2019 and based in Noida, India, is a global supplier of life science products and comprehensive solutions. The company's operations are divided into three core divisions: Specialty Chemicals, Nutrition & Heal...
Jubilant Ingrevia Ltd. Financial Statement Overview
Summary
Financials are mixed: revenue has returned to modest growth and leverage remains manageable, but profitability is below prior-cycle highs and gross margin has been volatile. Cash flow quality is the main weakness, with weak cash conversion versus earnings and volatile free cash flow (including prior negative years and a sharp decline in the latest year vs FY2025).
Income Statement
63PositiveBalance Sheet
72PositiveCash Flow
49Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 48.88B | 43.88B | 41.24B | 41.00B | 47.40B | 49.14B |
| Gross Profit | 21.00B | 10.74B | 19.00B | 18.50B | 20.44B | 19.56B |
| EBITDA | 7.26B | 5.94B | 5.56B | 4.56B | 5.79B | 8.59B |
| Net Income | 3.51B | 2.78B | 2.51B | 1.83B | 3.07B | 4.77B |
Balance Sheet | ||||||
| Total Assets | 59.99B | 54.84B | 50.32B | 47.32B | 42.59B | 37.97B |
| Cash, Cash Equivalents and Short-Term Investments | 2.42B | 1.90B | 1.15B | 828.36M | 1.08B | 454.69M |
| Total Debt | 8.95B | 7.92B | 7.64B | 7.40B | 4.07B | 2.38B |
| Total Liabilities | 26.83B | 23.58B | 21.05B | 19.94B | 15.93B | 13.64B |
| Stockholders Equity | 33.16B | 31.26B | 29.27B | 27.37B | 26.66B | 24.33B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 1.63B | 1.42B | -1.38B | -189.30M | 2.23B |
| Operating Cash Flow | 0 | 4.62B | 5.08B | 4.30B | 4.62B | 4.53B |
| Investing Cash Flow | 0 | -2.77B | -3.93B | -5.70B | -4.72B | -718.56M |
| Financing Cash Flow | 0 | -923.50M | -1.29B | 1.44B | 416.00M | -4.18B |
Jubilant Ingrevia Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JUBLINGREA, the sentiment is Negative. The current price of 588.90 is below the 20-day moving average (MA) of 589.98, below the 50-day MA of 622.67, and below the 200-day MA of 653.38, indicating a bearish trend. The MACD of -10.60 indicates Negative momentum. The RSI at 45.30 is Neutral, neither overbought nor oversold. The STOCH value of 54.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JUBLINGREA.
Jubilant Ingrevia Ltd. Peers Comparison
Overall Rating
IN:SYNGENE60.6Neutral
IN:CONCORDBIO57Neutral
IN:PPLPHARMA56Neutral
IN:JUBLINGREA53Neutral
IN:ONESOURCE48Neutral
IN:DCAL43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | INR 175.21B | 93.81 | ― | 0.29% | -5.99% | -60.30% | |
| 57Neutral | INR 116.17B | 41.14 | ― | 1.36% | 4.02% | -12.81% | |
| 56Neutral | INR 319.92B | -152.55 | ― | 0.06% | 9.43% | -767.49% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 53Neutral | INR 93.80B | 26.49 | ― | 0.85% | 15.41% | 21.76% | |
| 48Neutral | INR 181.34B | -10538.67 | ― | ― | 10.66% | -104.59% | |
| 43Neutral | INR 20.40B | 29.96 | ― | ― | -20.86% | -34.51% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:JUBLINGREA | Jubilant Ingrevia Ltd. | 588.90 | -119.43 | -16.86% | |
| IN:CONCORDBIO | Concord Biotech Ltd. | 555.20 | -165.09 | -22.92% | |
| IN:DCAL | Dishman Carbogen Amcis Ltd. | 130.10 | -112.05 | -46.27% | |
| IN:PPLPHARMA | Piramal Pharma Limited | 240.30 | 51.45 | 27.24% | |
| IN:SYNGENE | Syngene International Ltd. | 434.05 | -199.11 | -31.45% | |
| IN:ONESOURCE | OneSource Specialty Pharma Limited | 1581.35 | -124.50 | -7.30% |
Jubilant Ingrevia Ltd. Corporate Events
Jubilant Ingrevia Enters Electronics Design and Manufacturing Services
Jubilant Ingrevia Limited is a specialty chemicals and CDMO company with manufacturing and customer-focused capabilities. Its focus includes semiconductor and electronics chemicals, alongside services for customers in advanced electronics and related...
Jubilant Ingrevia to Buy 40% Stake in Zettaone, Pushing into Electronics and Semiconductor Services
Jubilant Ingrevia Limited has approved a binding term sheet to acquire a 40% strategic equity stake in Zettaone Technologies India Pvt. Ltd., an integrated electronics design and manufacturing platform, for approximately ₹189.2 crore in cash. The tra...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 28, 2026
